Logo image of ATNM

ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:ATNM - US00507W2061 - Common Stock

1.43 USD
+0.03 (+2.14%)
Last: 12/9/2025, 8:04:00 PM
1.42 USD
-0.01 (-0.7%)
Pre-Market: 12/10/2025, 9:26:17 AM
Fundamental Rating

2

ATNM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. ATNM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ATNM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATNM had negative earnings in the past year.
In the past year ATNM has reported a negative cash flow from operations.
ATNM had negative earnings in each of the past 5 years.
In the past 5 years ATNM reported 4 times negative operating cash flow.
ATNM Yearly Net Income VS EBIT VS OCF VS FCFATNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

ATNM's Return On Assets of -65.12% is on the low side compared to the rest of the industry. ATNM is outperformed by 60.45% of its industry peers.
ATNM has a Return On Equity of -215.83%. This is in the lower half of the industry: ATNM underperforms 70.62% of its industry peers.
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROIC N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ATNM Yearly ROA, ROE, ROICATNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNM Yearly Profit, Operating, Gross MarginsATNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

4

2. Health

2.1 Basic Checks

ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATNM has more shares outstanding than it did 1 year ago.
ATNM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ATNM has been reduced compared to a year ago.
ATNM Yearly Shares OutstandingATNM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ATNM Yearly Total Debt VS Total AssetsATNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATNM has an Altman-Z score of -9.56. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.56, ATNM is not doing good in the industry: 72.50% of the companies in the same industry are doing better.
ATNM has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ATNM (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.56
ROIC/WACCN/A
WACC8.81%
ATNM Yearly LT Debt VS Equity VS FCFATNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 71.37% of the companies in the same industry.
A Quick Ratio of 7.34 indicates that ATNM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.34, ATNM is in the better half of the industry, outperforming 71.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.34
Quick Ratio 7.34
ATNM Yearly Current Assets VS Current LiabilitesATNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.43%, which is quite impressive.
ATNM shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.55% on average over the next years. This is quite good.
Based on estimates for the next years, ATNM will show a very strong growth in Revenue. The Revenue will grow by 266.09% on average per year.
EPS Next Y13.26%
EPS Next 2Y16.68%
EPS Next 3Y6.29%
EPS Next 5Y14.55%
Revenue Next Year-76.23%
Revenue Next 2Y911.47%
Revenue Next 3Y526.75%
Revenue Next 5Y266.09%

3.3 Evolution

ATNM Yearly Revenue VS EstimatesATNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ATNM Yearly EPS VS EstimatesATNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNM Price Earnings VS Forward Price EarningsATNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNM Per share dataATNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.68%
EPS Next 3Y6.29%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATNM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACTINIUM PHARMACEUTICALS INC

NYSEARCA:ATNM (12/9/2025, 8:04:00 PM)

Premarket: 1.42 -0.01 (-0.7%)

1.43

+0.03 (+2.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners19.89%
Inst Owner Change-5.32%
Ins Owners2.36%
Ins Owner Change-1.12%
Market Cap44.62M
Revenue(TTM)N/A
Net Income(TTM)-41.04M
Analysts81.82
Price Target5.1 (256.64%)
Short Float %2.8%
Short Ratio3.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-20.9%
Min EPS beat(2)-80.18%
Max EPS beat(2)38.38%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-80.18%
Max EPS beat(4)44.95%
EPS beat(8)6
Avg EPS beat(8)11.58%
EPS beat(12)7
Avg EPS beat(12)2.81%
EPS beat(16)8
Avg EPS beat(16)-7.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)11.42%
EPS NQ rev (3m)11.42%
EPS NY rev (1m)19.1%
EPS NY rev (3m)19.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.35
P/tB 2.35
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0
BVpS0.61
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -65.12%
ROE -215.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.19%
ROA(5y)-40.57%
ROE(3y)-100.2%
ROE(5y)-74.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.34
Quick Ratio 7.34
Altman-Z -9.56
F-Score2
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)25.77%
Cap/Depr(5y)31.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%56.76%
EPS Next Y13.26%
EPS Next 2Y16.68%
EPS Next 3Y6.29%
EPS Next 5Y14.55%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-76.23%
Revenue Next 2Y911.47%
Revenue Next 3Y526.75%
Revenue Next 5Y266.09%
EBIT growth 1Y5.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.87%
EBIT Next 3Y1.85%
EBIT Next 5Y-1.39%
FCF growth 1Y27.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.29%
OCF growth 3YN/A
OCF growth 5YN/A

ACTINIUM PHARMACEUTICALS INC / ATNM FAQ

What is the fundamental rating for ATNM stock?

ChartMill assigns a fundamental rating of 2 / 10 to ATNM.


What is the valuation status of ACTINIUM PHARMACEUTICALS INC (ATNM) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACTINIUM PHARMACEUTICALS INC (ATNM). This can be considered as Overvalued.


Can you provide the profitability details for ACTINIUM PHARMACEUTICALS INC?

ACTINIUM PHARMACEUTICALS INC (ATNM) has a profitability rating of 0 / 10.